Editas Medicine to Present at the 38th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. EDIT, a leading genome editing company, today announced that it will present a company overview followed by a question and answer session at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020, at 10:30 a.m. PT (1:30 p.m. ET) in San Francisco, CA.

A live webcast of the presentation and question and answer session will be available on the Investors & Media section of the Editas Medicine website at www.editasmedicine.com.  An archived replay will be available for approximately 30 days following the presentation.

Aboutimage desc for 49 Editas Medicine

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Contacts:

Investors

Mark Mullikin

(617) 401-9083

mark.mullikin@editasmed.com

Media

Cristi Barnett

(617) 401-0113

cristi.barnett@editasmed.com

Primary Logo

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsHealth CarePress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!